Tysabri
PreclinicalSmall molecule
BiogenTysabri is one of 67 small molecule programs targeting Fatigue. It is currently in Preclinical.
3
Indications
8
Total Trials
1
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
138 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Vumerity
BiogenPhase 3
Mayzent
NovartisPhase 3
Activated Charcoal
SanofiPhase 3
Antihistamine
Arrowhead PharmaceuticalsPhase 3
MRI Contrast-Enhancing Agents
SanofiPhase 3
Frexalimab
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Sclerosis4 trials
Multiple Sclerosis, Relapsing-Remitting1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tysabri. EMBL-EBI & Wellcome Sanger Institute.
- [4]